Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. 2016

Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.

OBJECTIVE The study aims were to determine whether inactivated influenza A/H5N1 vaccine administration elicited cell mediated immune (CMI) responses and the impact of adjuvant, vaccine dose and subject age on these responses. METHODS Adults who were previously primed with either adjuvanted or unadjuvanted, inactivated, A/H5N1/Vietnam/1203/2004 (Clade 1) vaccine or unprimed (received placebo) in previous vaccine studies were randomized to receive one (primed) or two (unprimed) 15- or 90-mcg doses of inactivated, A/H5N1/Indonesia/05/05 (Clade 2) vaccine. Peripheral blood mononuclear cells (PBMCs) were collected and analyzed from a subset of vaccinees to assess CMI responses using IFN-γ and granzyme B ELISPOT assays. Cytokine measurements were performed on PBMC supernatants after stimulation with H5N1 virus. RESULTS PBMCs were available from 177 participants; 88 and 89 received 15-mcg and 90-mcg of unadjuvanted clade 2 vaccine, respectively. Following H5N1 clade 1 stimulation, IFN-γ but not granzyme B normalized spot-forming cell numbers had statistically significant increased numbers at each of the post-vaccination timepoints compared to baseline in pooled analyses of all vaccine doses and age groups. Clade 2 stimulation resulted in statistically significant increased numbers of IFN-γ cells only 180 days following the last vaccination. Responses were similar among younger and older study participants, as were responses among those primed with alum-adjuvanted or non-adjuvanted clade 1 H5N1 vaccines. The dosage of clade 2 vaccine did not impact CMI responses among primed subjects, but responses were statistically significantly greater in unprimed recipients of the 90-mcg dosage compared to unprimed recipients of the 15-mcg dosage. IFN-γ levels in the supernatants of stimulated PBMC were strongly correlated with IFN-γ ELISPOT results. CONCLUSIONS CMI responses occur in adults administered influenza A/H5N1 inactivated influenza vaccine.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
January 2008, PloS one,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
January 2012, The Journal of infectious diseases,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
December 2013, Virus research,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
January 2015, Human vaccines & immunotherapeutics,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
May 2006, Vaccine,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
June 2006, The New England journal of medicine,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
June 2006, The New England journal of medicine,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
December 2016, International journal of biological macromolecules,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
May 2015, The Journal of infectious diseases,
Innocent N Mbawuike, and Robert L Atmar, and Shital M Patel, and David B Corry, and Patricia L Winokur, and Rebecca C Brady, and Wilbur H Chen, and Kathryn M Edwards, and C Buddy Creech, and Emmanuel B Walter, and Sharon E Frey, and Robert B Belshe, and Johannes B Goll, and Heather Hill, and Wendy A Keitel
March 2012, Influenza and other respiratory viruses,
Copied contents to your clipboard!